Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy

Infants with KMT2A-rearranged B-cell acute lymphoblastic leukemia (ALL) have a dismal prognosis. Survival outcomes have remained static in recent decades despite treatment intensification and novel therapies are urgently required. KMT2A-rearranged infant ALL cells are characterized by an abundance of promoter hypermethylation and exhibit high BCL-2 expression, highlighting potential for therapeutic targeting. Here, we show that hypomethylating agents exhibit in vitro additivity when combined with most conventional chemotherapeutic agents. However, in a subset of samples an antagonistic effect was seen between several agents. This was most evident when hypomethylating agents were combined with methotrexate, with upregulation of ATP-binding cassette transporters identified as a potential mechanism. Single agent treatment with azacitidine and decitabine significantly prolonged in vivo survival in KMT2A-rearranged infant ALL xenografts. Treatment of KMT2A-rearranged infant ALL cell lines with azacitidine and decitabine led to differential genome-wide DNA methylation, changes in gene expression and thermal proteome profiling revealed the target protein-binding landscape of these agents. The selective BCL-2 inhibitor, venetoclax, exhibited in vitro additivity in combination with hypomethylating or conventional chemotherapeutic agents. The addition of venetoclax to azacitidine resulted in a significant in vivo survival advantage indicating the therapeutic potential of this combination to improve outcome for infants with KMT2A-rearranged ALL.

Automated summary

In infants with KMT2A-rearranged B-cell acute lymphoblastic leukemia (ALL), hypomethylating agents combined with most conventional chemotherapeutic agents showed additive effects in vitro, but antagonistic effects were observed in a subset of samples. Single agent treatment with azacitidine and decitabine significantly prolonged in vivo survival in KMT2A-rearranged infant ALL xenografts. Differential genome-wide DNA methylation, changes in gene expression, and thermal proteome profiling were observed in KMT2A-rearranged infant ALL cell lines treated with azacitidine and decitabine. The selective BCL-2 inhibitor, venetoclax, exhibited in vitro additivity when combined with hypomethylating or conventional chemotherapeutic agents. Addition of venetoclax to azacitidine resulted in a significant in vivo survival advantage, indicating the therapeutic potential of this combination in improving outcomes for infants with KMT2A-rearranged ALL.